Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310439 | 1.00 | PRKCI (0.55) | PRKCICYP2A6CA1CA2PIK3CB | |
| SCHEMBL16633327 | 0.88 | PRKCI (0.55) | PRKCICYP2A6PIK3CBHSD11B1MAOB | |
| SCHEMBL593671 | 0.84 | CYP2A6 (0.50) | PRKCICYP2A6CA1CA2PIK3CB | |
| SCHEMBL31326584 | 0.84 | CYP2A6 (0.50) | PRKCICYP2A6CA1CA2PIK3CB | |
| SCHEMBL3965798 | 0.78 | TUBB4A (0.44) | CA1CA2TUBB4ATUBBTUBA3C | |
| SCHEMBL29952406 | 0.78 | TUBB4A (0.44) | CA1CA2TUBB4ATUBBTUBA3C | |
| SCHEMBL2627966 | 0.77 | CA2 (0.39) | PRKCICYP2A6CA1CA2 | |
| SCHEMBL1400341 | 0.75 | PRKCI (0.59) | PRKCICYP2A6PIK3CBHSD11B1MAOB | |
| SCHEMBL29874172 | 0.75 | PRKCI (0.59) | PRKCICYP2A6PIK3CBHSD11B1MAOB | |
| SCHEMBL2693281 | 0.74 | PRKCI (0.41) | PRKCICYP2A6PIK3CBHSD11B1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024213877-A1 | PROCESS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-10-17 | — | — | WO | disclosed |
| US-20240246908-A1 | TEAD INHIBITORS | ORION CORPORATION (FI) | 2024-07-25 | — | — | US | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | ARISAN THERAPEUTICS INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | ARISAN THERAPEUTICS INC. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281825-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | C9, C1S, ZC3HAV1 | PRKCI 3648/4885CYP2A6 1921/4885CA1 3862/4885 |
| US-20230303569-A1 | HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | C3AR1, C9, C1R | PRKCI 4364/4885CYP2A6 352/4885CA1 2741/4885 |
| US-11352328-B2 | Heterocyclic compounds for the treatment of arenavirus | C9, C1R, C1S | PRKCI 3791/4885CYP2A6 1787/4885CA1 3345/4885 |
| US-20240246908-A1 | TEAD INHIBITORS | TEAD3, TEAD1, TEAD2 | PRKCI 3348/4885CYP2A6 2190/4885CA1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.